دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol
Gregory G.SchwartzMD, PhDaMichaelSzarekPhDbcVera A.BittnerMD, MSPHdRafaelDiazMDeShaun G.GoodmanMDfgJ. WouterJukemaMD, PhDhiUlfLandmesserMDjPatricioL?pez-JaramilloMDkGarenManvelianMDlRobertPordyMDlMichelScemamaMDmPeter R.SinnaeveMDnHarvey D.WhiteDScoPhGabriel StegMDpq
doi : 10.1016/j.jacc.2021.04.102
Volume 78, Issue 5, 3 August 2021, Pages 421-433
Guidelines recommend nonstatin lipid-lowering agents in patients at very high risk for major adverse cardiovascular events (MACE) if low-density lipoprotein cholesterol (LDL-C) remains ?70 mg/dL on maximum tolerated statin treatment. It is uncertain if this approach benefits patients with LDL-C near 70 mg/dL. Lipoprotein(a) levels may influence residual risk.
The Residual Risk Odyssey: From LDL to Lp(a)?
Robert S.RosensonMDaSascha N.GoonewardenaMDb
doi : 10.1016/j.jacc.2021.04.103
Volume 78, Issue 5, 3 August 2021, Pages 434-436
Frequent LPA KIV-2 Variants Lower Lipoprotein(a) Concentrations and Protect Against Coronary Artery Disease
Johanna F.Schachtl-RiessMScaAzinKheirkhahMScaRebeccaGrüneisMScaSilviaDi MaioMScaSebastianSchoenherrPhDaGertraudStreiterBScaJamie LeeLossoBScaBernhardPaulweberMDbKai-UweEckardtMDcdAnnaK?ttgenMD, MPHeClaudiaLaminaPhDaFlorianKronenbergMDa?StefanCoassinPhDa?
doi : 10.1016/j.jacc.2021.05.037
Volume 78, Issue 5, 3 August 2021, Pages 437-449
Lipoprotein(a) (Lp(a)) concentrations are a major independent risk factor for coronary artery disease (CAD) and are mainly determined by variation in LPA. Up to 70% of the LPA coding sequence is located in the hypervariable kringle IV type 2 (KIV-2) region. It is hardly accessible by conventional technologies, but may contain functional variants.
Genetics to the Rescue: Sophisticated Approaches Provide Critical Insights Into the Determination of Lp(a) Levels?
Marlys L.KoschinskyPhDabMichael B.BoffaPhDac
doi : 10.1016/j.jacc.2021.06.004
Volume 78, Issue 5, 3 August 2021, Pages 450-452
Cardiovascular and Kidney Outcomes Across the Glycemic Spectrum: Insights From the UK Biobank
Michael C.HonigbergMD, MPPabcdSeyedeh M.ZekavatBSbceJames P.PirruccelloMDabcdPradeepNatarajanMD, MMScabcdMuthiahVaduganathanMD, MPHdf
doi : 10.1016/j.jacc.2021.05.004
Volume 78, Issue 5, 3 August 2021, Pages 453-464
Treatment guidelines for prediabetes primarily focus on glycemic control and lifestyle management. Few evidence-based cardiovascular and kidney risk-reduction strategies are available in this population.
Closing the Glycemic Divide: The Time for Preventive Cardiology Is Now?
Michael D.ShapiroDO, MCRaBorjaIbanezMD, PhDbcd
doi : 10.1016/j.jacc.2021.05.040
Volume 78, Issue 5, 3 August 2021, Pages 465-467
Pulmonary-to-Systemic Arterial Shunt to Treat Children With Severe Pulmonary Hypertension
R. MarkGradyMDaMatthew W.CanterMETbFeiWanPhDbAnton A.ShmaltsMDcRyan D.ColemanMDdMauriceBeghettiMDeRolf M.F.BergerMD, PhDfMaria J.del Cerro MarinMD, PhDgScott E.FletcherMDhRusselHirschMDiTilmanHumplMDjD. DunbarIvyMDkEdward C.KirkpatrickDOlThomas J.KulikMDmMarilyneLevyMD, PhDnShahinMoledinaMDoDelphineYungMDpPiroozEghtesadyMD, PhDbDamienBonnetMD, PhDnon behalf of the
doi : 10.1016/j.jacc.2021.05.039
Volume 78, Issue 5, 3 August 2021, Pages 468-477
The placement of a pulmonary-to-systemic arterial shunt in children with severe pulmonary hypertension (PH) has been demonstrated, in relatively small studies, to be an effective palliation for their disease.
Reverse Potts Shunt for Pulmonary Hypertension: Back to a “Fetal” Circulation in Part??
DietmarSchranzMD, PhD
doi : 10.1016/j.jacc.2021.05.038
Volume 78, Issue 5, 3 August 2021, Pages 478-480
Molecular Aspects of Lifestyle and Environmental Effects in Patients With Diabetes: JACC Focus Seminar
MatthewNayorMD, MPHaSvati H.ShahMD, MS, MHSbcVenkateshMurthyMD, PhDdeRavi V.ShahMDa
doi : 10.1016/j.jacc.2021.02.070
Volume 78, Issue 5, 3 August 2021, Pages 481-495
Diabetes is characterized as an integrated condition of dysregulated metabolism across multiple tissues, with well-established consequences on the cardiovascular system. Recent advances in precision phenotyping in biofluids and tissues in large human observational and interventional studies have afforded a unique opportunity to translate seminal findings in models and cellular systems to patients at risk for diabetes and its complications. Specifically, techniques to assay metabolites, proteins, and transcripts, alongside more recent assessment of the gut microbiome, underscore the complexity of diabetes in patients, suggesting avenues for precision phenotyping of risk, response to intervention, and potentially novel therapies. In addition, the influence of external factors and inputs (eg, activity, diet, medical therapies) on each domain of molecular characterization has gained prominence toward better understanding their role in prevention. Here, the authors provide a broad overview of the role of several of these molecular domains in human translational investigation in diabetes.
Genetics of Type 2 Diabetes: Opportunities for Precision Medicine: JACC Focus Seminar
Daniel SeungKimMD, PhD, MPHaAnna L.GloynDPhilbcJoshua W.KnowlesMD, PhDacd
doi : 10.1016/j.jacc.2021.03.346
Volume 78, Issue 5, 3 August 2021, Pages 496-512
Type 2 diabetes (T2D) is highly prevalent and is a strong contributor for cardiovascular disease. However, there is significant heterogeneity in disease pathogenesis and the risk of complications. Enormous progress has been made in our ability to catalog genetic variation associated with T2D risk and variation in disease-relevant quantitative traits. These discoveries hold the potential to shed light on tractable targets and pathways for safe and effective therapeutic development, but the promise of precision medicine has been slow to be realized. Recent studies have identified subgroups of individuals with differential risk for intermediate phenotypes (eg, lipid levels, fasting insulin, body mass index) that contribute to T2D risk, helping to account for the observed clinical heterogeneity. These “partitioned genetic risk scores” not only have the potential to identify patients at greatest risk of cardiovascular disease and rapid disease progression, but also could aid patient stratification bridging the gap toward precision medicine for T2D.
Management of Obesity in Cardiovascular Practice: JACC Focus Seminar
Jean-PierreDesprésCQ, PhDabcAndré C.CarpentierMDdeAndréTchernofPhDbfIan J.NeelandMDgPaulPoirierMD, PhDbh
doi : 10.1016/j.jacc.2021.05.035
Volume 78, Issue 5, 3 August 2021, Pages 513-531
Obesity contributes to reduced life expectancy because of its link with type 2 diabetes and cardiovascular disease. Yet, targeting this poorly diagnosed, ill-defined, and underaddressed modifiable risk factor remains a challenge. In this review, we emphasize that the tendency among health care professionals to amalgam all forms of obesity altogether as a single entity may contribute to such difficulties and discrepancies. Obesity is a heterogeneous condition both in terms of causes and health consequences. Attention should be given to 2 prevalent subgroups of individuals: 1) patients who are overweight or moderately obese with excess visceral adipose tissue; and 2) patients with severe obesity, the latter group having distinct additional health issues related to their large body fat mass. The challenge of tackling high-cardiovascular-risk forms of obesity through a combination of personalized clinical approaches and population-based solutions is compounded by the current obesogenic environment and economy.
Different Paths for Careers in Structural Heart Disease: Trainees Perspective
RimHalabyMDaSameerHirjiMD, MPHbJasonHanMDc
doi : 10.1016/j.jacc.2021.04.104
Volume 78, Issue 5, 3 August 2021, Pages 532-536
RESPONSE: Approaching Truly Collaborative Training in Structural Heart Disease: Seeking the Middle Path
Hubert Y.LuuMD, MSTom C.NguyenMD
doi : 10.1016/j.jacc.2021.04.108
Volume 78, Issue 5, 3 August 2021, Pages 535-536
Coronary Artery Calcium Scoring for Adults at Borderline 10-Year ASCVD Risk: The CAC Consortium
S.M. IftekharUddinMD, MSPHAlbert D.OseiMD, MPHOlufunmilayoObisesanMD, MPHOmarDzayeMD, PhDZeinaDardariMSMichael D.MiedemaMD, MPHJohn A.RumbergerMD, PhDDaniel S.BermanMDMatthew J.BudoffMDMichael J.BlahaMD, MPH
doi : 10.1016/j.jacc.2021.05.036
Volume 78, Issue 5, 3 August 2021, Pages 537-538
Percutaneous DLC-Based Total Cavopulmonary Assist Achieves 96-Hour Survival in Lethal Cavopulmonary Failure Sheep
LiLiMDJingkunWangMDGuangfengZhaoPhDStephenTopazMD, BSDavidMoralesMDAjitYoganathanPhDCherryBallard-CroftPhDJoseph B.ZwischenbergerMDDongfangWangMD, PhD
doi : 10.1016/j.jacc.2021.06.003
Volume 78, Issue 5, 3 August 2021, Pages 538-540
Cardiac Angiotensin II Is Generated Locally by ACE and Not Chymase
Edwyn O.Cruz-L?pezMScEstrellitaUijlMDA.H. JanDanserPhD
doi : 10.1016/j.jacc.2021.04.101
Volume 78, Issue 5, 3 August 2021, Pages 540-541
Advanced Heart Failure and Angiotensin System Fascinating Complexities
AnastasiaShchendryginaMD, PhDNathanMewtonMD, PhDAnja ZupanMeznarMD, MSc
doi : 10.1016/j.jacc.2021.04.100
Volume 78, Issue 5, 3 August 2021, Pages 541-542
Use of Nonspecific Protease Inhibitors in Research: An Underestimated Problem
EmilieDe HertPharmDIngridDe MeesterPharmD, PhD
doi : 10.1016/j.jacc.2021.05.034
Volume 78, Issue 5, 3 August 2021, Pages 542-543
Reply: Myocardial Angiotensin Relationships in Heart Failure: Long Way Beyond, Long Way Ahead
NoemiPavoMD, PhDSuriyaPrausmüllerMDPhilipp E.BartkoMD, PhDGeorgGoliaschMD, PhDMartinHülsmannMD
doi : 10.1016/j.jacc.2021.06.002
Volume 78, Issue 5, 3 August 2021, Pages 543-544
